Autopsy report · NCT05691478
A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma
Cause of deathOther
“Other - Extend the observation period for current patients”
Life of this trial
- Registered 2 months before it started.
- Suspended: paused, and may or may not restart.
- 1,122 participants planned (an estimate, not an actual count).
Vital statistics
- Status
- Suspended
- Phase
- Phase 2, Phase 3
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- High Grade Osteosarcoma; Localized Osteosarcoma; Metastatic Osteosarcoma; Secondary Osteosarcoma
- Interventions
- Bone Scan; Cabozantinib S-malate; Cisplatin; Computed Tomography; Doxorubicin Hydrochloride; Magnetic Resonance Imaging
- Participants
- 1,122 (planned, not actual)
- Sites
- 202
- Countries
- Australia, Canada, New Zealand, United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.